4ème symposium WIN 2012

Le 4ème Symposium WIN, qui se tiendra à Paris les 28 et 29 juin 2012 (WIN 2012), sera cette année encore un forum unique rassemblant des intervenants internationaux de haut rang issus du monde universitaire, de l’industrie et des autorités de réglementation.

Ils examineront les moyens d’améliorer l’efficacité des thérapies anti-cancer personnalisée à chaque patient, grâce à l’optimisation de l’utilisation de biomarqueurs et de traitements anti-cancer innovants.

The Worldwide Innovative Networking (WIN) Consortium invites you to attend the WIN 2012 Symposium, to be held in  Paris, June 28-29, 2012.

This symposium will be the next in the successful series of annual meetings dedicated to personalized cancer medicine.

The WIN Consortium was created to accelerate the pace and reduce the cost of translating effective cancer treatments to the bedside

The main theme of the 2012 symposium will be Efficacy of biomarkers and personalized cancer therapeutics. This theme will be elaborated in various plenary sessions.


Venue : Palais des Congrès de Paris, 2 place de la Porte Maillot - 75017 Paris, France

WIN 2012 brings together a unique assembly of top speakers, contributing to the following sessions

Opening address

Alexander Eggermont, Cancer Institute 
        Gustave Roussy, France


Fundamental concepts and strategies to improve efficacy of therapeutics

  • Fabien Calvo, French National Cancer Institute, France
  • Ronald DePinho, UT MD Anderson Cancer Center, USA
  • James Doroshow, National Cancer Institute, USA
  • Edison Liu, Human Genome Organisation HUGO & Jackson Laboratory, USA
  • Christopher A. Viehbacher, CEO, Sanofi


WIN Consortium – Global innovative clinical trials 

  • Fabrice Andre, Cancer Institute Gustave Roussy, France
  • Raanan Berger, Chaim Sheba Medical Center, Israel
  • Razelle Kurzrock, UT MD Anderson Cancer Center, USA
  • Vladimir Lazar, WIN Consortium & Cancer Institute Gustave Roussy, France
  • John Mendelsohn, WIN Consortium & UT MD Anderson Cancer Center, USA
  • Mike Pellini, Foundation Medicine Cambridge, USA
  • Sam Raha, Life Technologies, USA
  • Jean-Charles Soria, Cancer Institute Gustave Roussy, France
  • Josep Tabernero, Hospital Val d’ Hebron, Spain


Biology-driven diagnostics and therapeutics

  • Steven Averbuch, Bristol-Myers Squibb, USA
  • Rene Bernards, Netherlands Cancer Institute, The Netherlands
  • Richard Gaynor Eli Lilly and Company, USA
  • Paolo Paoletti, GlaxoSmithKline Oncology, USA
  • Bin Tean Teh, SingHealth Group, Singapore



Combinatorial biomarkers and efficacy of therapeutics

  • Waun Ki Hong,  University of Texas MD Anderson Cancer Center, USA
  • Jeffrey Jackson, Bristol-Myers Squibb, USA
  • Laurence Zitvogel,  Cancer Institute Gustave Roussy, France


Patient advocacy organizations

  • Janelle Hail, National Breast Cancer Foundation, USA


Innovative targets and new drug discoveries

  • Nick Botwood, AstraZeneca, UK
  • William Dalton, Lee Moffitt Cancer Center, USA
  • Elisabeth Mansfield, Food & Drug Administration, USA  
  • Christian Meisel, Translational Medicine Penzberg, Roche, Germany
  • Paul Workman, The Institute of Cancer Research, UK


Innovative therapeutics and clinical trials

  • Gerald Batist, McGill University & Segal Cancer Center,  Canada
  • Stephen Friend, Sage Bionetworks, USA
  • Razelle Kurzrock, UT MD Anderson Cancer Center, USA
  • Patricia LoRusso,  Barbara Ann Karmanos Cancer Institute, USA
  • Josep Tabernero, Hospital Val d’ Hebron, Spain


System biology and bioinformatics

  • Leroy Hood, Institute for Systems Biology, USA
  • John Quackenbush, Dana-Farber Cancer Institute, Harvard School of Public Health, USA
  • Yosef Yarden, Weizmann Institute of Science, Israel


WIN 2012 symposium synthesis and perspectives

  • Richard Schilsky, Chairman SAB, WIN Consortium & University of Chicago, USA


Plus d'informations

Télécharger le programme

Inscription en ligne

Online abstract submission open; abstracts will be publised in an oncology journal